Idiopathic pulmonary fibrosis is a nonmalignant disease, yet it carries a prognosis akin to, or
even worse than, many cancers. Until recently, lung transplantation has been the only
therapeutic intervention that has offered any prospect of improved survival for individuals
with IPF. The past decade has, however, witnessed an explosion of interest in IPF. Triggered
by improved clinical phenotyping, this interest has led to major developments in
understanding of disease pathogenesis. The first true multicenter randomized trial of therapy …